Metabolic Reprogramming Target Analysis & High-Purity Mitochondrial Reagents for Cancer and Metabolic Disorder Development
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ATP5E/ATP5F1E drug discovery targeting mitochondrial ATP synthase modulation. Select your validation modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ATP5F1E Recombinant Protein (Full-length epsilon subunit, HEK293 expressed, >95% purity, Endotoxin <1EU/µg) | View ATP5F1E Products |
| Gene Delivery | ATP5F1E Lentivirus Particles (ORF with MTS for stable mitochondrial expression; CMV/EF1a promoter options) | View ATP5F1E Products |
| Benchmark Ab | Anti-ATP5F1E Recombinant mAb (Sequence-verified positive control for Western/IP) | View ATP5F1E Products |
| Validator | ATP5F1E siRNA Set (Validated knockdown for specificity confirmation in mitochondrial functional assays) | View ATP5F1E Products |
| Complex Partner | ATP5B Recombinant Protein (Beta subunit, catalytic core for heterodimerization/ATPase activity assays) | View ATP5B Products |
| Related Target A | ATP5F1A (Alpha subunit, conformational regulation and assembly scaffold) | View ATP5F1A Products |
| Related Target B | VDAC1 (Mitochondrial porin channel for metabolic flux and drug resistance studies) | View VDAC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| F1 Complex Assembly & Protein-Protein Interaction | Purified ATP5F1E + ATP5B available as matched pair; Sequence Verified; Suitable for SPR/BLI heterodimer binding studies |
| Mitochondrial Localization Verification | Lentivirus with MTS tag; HEK293 expression system preserves native import machinery compatibility |
| Cross-species Metabolic Model Translation | Human/Mouse/Cyno ATP5F1E ortholog proteins available with >95% purity; Endotoxin controlled for cellular metabolic assays |
| ATPase Activity Inhibition Screening | High-purity antigens enable enzymatic activity reconstruction; Compatible with malachite green and ADP-Glo assays |
| Compensatory Pathway Analysis | Matched HK2 and LDHA recombinant proteins available for glycolytic flux panel screening |
| Intracellular Target Engagement (CETSA/MSA) | High-concentration recombinant WT and mutant proteins; Theoretical MW by sequence |
| Off-target Subfamily Screening | Homologous ATP synthase subunit panel (ATP5F1A, ATP5B); Sequence Verified |
Live ATP5F1E R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The targeting of mitochondrial ATP synthase subunits, including ATP5F1E (epsilon subunit), represents a paradigm shift in metabolic disease therapeutics and oncology. While historically considered "undruggable" due to mitochondrial membrane permeability challenges, the emergence of lipophilic cation-conjugated inhibitors and allosteric modulators has revitalized the field. Current R&D focuses on disrupting the F1Fo complex rotational mechanics via the epsilon subunit's regulatory function, offering a distinct mechanism from traditional direct catalytic site inhibition. Major players are shifting focus from broad Complex V inhibitors to subunit-selective chemical probes and genetic modulation. As first-generation mitochondrial therapeutics reach Phase II for metabolic syndromes, the next wave of R&D is targeting ATP5F1E-specific conformational locks that prevent proton channel rotation, offering improved safety profiles over pan-ATPase inhibition. Key modalities include small molecule allosteric modulators, targeted protein degraders (PROTACs), and gene therapy/RNAi approaches for rare mitochondrial disorders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Allosteric Modulators | Agios Pharmaceuticals, Mitobridge (Astellas), Novartis | Metabolic Syndromes, Solid Tumors, Leukemia | Conformational Binding Assay (Need high-purity ATP5F1E/ATP5B complex proteins for SPR) |
| Targeted Protein Degraders (PROTACs) | Arvinas, Kymera Therapeutics | Refractory Cancers | Ternary Complex Validation (Need exact sequence recombinant antigens) |
| Gene Therapy / RNAi | Alnylam, Ionis | Mitochondrial Myopathies | Knockdown Baseline (Need Lentivirus/siRNA Validator Sets) |
| Peptide-Conjugated Cargos | MITO-Labs (Emerging) | Neurodegeneration | Mitochondrial Import Validation (Need MTS-tagged Lentivirus for localization studies) |
| Metabolic Combination Therapy | Oncology Biotechs | Drug-Resistant Cancers | Pathway Cross-Talk Analysis (Need ATP5F1E + HK2/LDHA protein panels for flux studies) |
Key Mutations & Disease Association
A key mutation in ATP5F1E is associated with Mitochondrial Complex V Deficiency Nuclear Type 3 (MC5DN3). The mutation is classified as likely pathogenic and is recorded in dbSNP as rs387906929 (UniProt P56381 VAR_066211). This mutation underscores the critical role of the epsilon subunit in ATP synthase function and highlights the need for mutant-specific reagents for drug resistance and disease modeling studies.